Quantcast

Latest Angiogenesis Stories

2014-02-11 08:33:10

CAMBRIDGE, Mass., Feb. 11, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in an open label single-arm Phase 2 clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) in patients with relapsed ovarian cancer. The Phase 2 combination therapy trial of this investigational treatment is being conducted at Massachusetts General Hospital (MGH) and...

2014-01-28 23:03:54

An early stage study shows melatonin – a hormone that regulates the body’s sleep and awake cycles – may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of São Paulo. Detroit, Michigan (PRWEB) January 28, 2014 An early stage study shows melatonin – a hormone that regulates the body’s sleep and awake cycles – may have the potential to...

Melatonin Therapy May Help Slow Breast Cancer Tumor Growth
2014-01-28 14:19:25

Brett Smith for redOrbit.com - Your Universe Online Produced by the brain in response to darkness and often taken as a sleep aid supplement, melatonin could be effective in slowing the growth of certain breast cancer tumors, according to a new report published in the open-access journal PLOS ONE. More specifically, melatonin may stunt tumor growth and tumor cell production, as well as obstruct the generation of new blood vessels in breast cancer cells that test negative for estrogen...

2014-01-27 08:28:34

SAN DIEGO, Jan. 27, 2014 /PRNewswire/ -- Cardium Therapeutics Inc. (Ticker Symbol: CRXM) reported on the Company's strategic focus on its two advanced regenerative medicine therapeutics, based on encouraging preliminary findings from its Generx(®) Aspire International Phase 3 registration clinical study, and data on the utility of Excellagen(®) for wound healing and as a biologics delivery platform. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Based on these...

Computer Simulation Of Blood Vessel Growth Is An Early Step Toward Treatment For Diseases That Affect Blood Flow
2014-01-23 15:46:37

University of Utah University of Utah bioengineers showed that tiny blood vessels grow better in the laboratory if the tissue surrounding them is less dense. Then the researchers created a computer simulation to predict such growth accurately – an early step toward treatments to provide blood supply to tissues damaged by diabetes and heart attacks and to skin grafts and implanted ligaments and tendons. "Better understanding of the processes that regulate the growth of blood vessels...

2014-01-21 10:21:17

Cancer cells have something that every prisoner longs for—a master key that allows them to escape. A study in The Journal of Cell Biology describes how a protein that promotes tumor growth also enables cancer cells to use this key and metastasize. Unless it can enter a blood or lymphatic vessel, a cancer cell is imprisoned in the tissue where it arises. The growth factor VEGF is the tumor cell's master key. It loosens connections between endothelial cells that form the lining of blood...

2014-01-21 08:26:51

CAMBRIDGE, Mass., Jan. 21, 2014 /PRNewswire/ -- The Angiogenesis Foundation, in collaboration with musician/activist Peter Gabriel, has launched the Do iT Yourself Health Revolution(SM), an outside-of-the-box solution to wellness that puts practical actions, informed by scientific evidence, into the hands of the people. "The current healthcare system is intrinsically flawed because it is designed to chase and treat diseases, rather than keep people healthy in the first place,"...

2014-01-13 16:26:26

GENEVA, Jan. 13, 2014 /PRNewswire/ -- Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs announced today that Opthea Pty Ltd has entered into a commercial license agreement with Selexis covering the use of the CHO-M Cell Line and related technologies for the production of OPT-302 (formerly VGX-300), an Fc fusion protein for the treatment of wet Age-Related...

2014-01-13 08:29:57

CAMBRIDGE, Mass., Jan. 13, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has achieved its primary efficacy endpoint in an ongoing single-arm Phase 2 monotherapy clinical trial in relapsed ovarian cancer. The ongoing open label Phase 2 monotherapy trial is being conducted at Massachusetts General Hospital and the affiliated Harvard teaching hospitals under the direction of principal investigator,...

2014-01-03 15:47:18

A protein that has been at the center of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA). The most advanced version of αvβ3-integrin antagonists failed clinical trials to treat aggressive forms of brain cancer. But research published today in the American Heart Association’s journal Circulation Research shows that targeting the protein in question could still be vital in stopping the growth of...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related